DNA immunogenic composition comprising a full-length modified poxvirus L1R gene fused to a tPA leader sequence
US8513005B2 · kind B2 · utility
3Cited by
5References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 7, 2008 |
| Grant date | Aug 20, 2013 |
| Priority date | — |
| Expiry date | Nov 3, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/24134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention described here encompasses DNA and protein vaccines against poxviruses, and relevant immunogenic compositions, comprising at a minimum a nucleic acid encoding a modified full-length poxvirus L1R gene or its ortholog. The L1R gene is modified so that an endoplasmic reticulum-targeting sequence is operably linked on the 5′ end. Preferably the nucleic acid sequences for other poxviruses antigens are also included, such as A33R, B5R and/or A27L. These vaccines and compositions provide improved neutralizing antibody response elicited by molecular poxvirus vaccines, over known vaccines using unmodified L1R.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.